Norden Gregory 4

What Happened
Norden Gregory, a director of Royalty Pharma plc (RPRX), sold 3,045 shares in an open‑market transaction on May 14, 2026. The shares were sold at $53.00 per share for a total proceeds of $161,385. This was a sale (disposition) rather than a purchase; such sales can be routine, and this one was executed under a prearranged 10b5-1 trading plan.

Key Details

• Transaction date: 2026-05-14; Price: $53.00 per share; Shares sold: 3,045; Total value: $161,385.
• Transaction type: Sale (code S) — open market/private sale as reported.
• Footnote: Transaction effected pursuant to a 10b5-1 plan adopted by the reporting person on February 12, 2026.
• Filing: Form 4 filed 2026-05-15 (timely next‑day filing).
• Shares owned after transaction: Not specified in the provided report.

Context
A 10b5-1 plan indicates the trade was prearranged, which often reduces the interpretive value of the sale as a signal about the insider’s current view of the company. For retail investors, purchases typically carry more weight as affirmative signals; routine sales by directors are common for liquidity or diversification reasons and do not by themselves indicate company performance.